A carregar...

The OlympiAD trial: who won the gold?

OlympiAD was a phase 3 randomized controlled trial of a PARP inhibitor olaparib for metastatic HER2 negative breast cancer patients harboring a BRCA mutation. Although the OlympiAD trial met its primary endpoint, there are concerns regarding whether olaparib truly improves meaningful outcomes for th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ecancermedicalscience
Autor principal: Gyawali, Bishal
Formato: Artigo
Idioma:Inglês
Publicado em: Cancer Intelligence 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739869/
https://ncbi.nlm.nih.gov/pubmed/29290761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2017.ed75
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!